Cystic fibrosis: regulation of chronic infections
The Air Liquide Foundation supports the Institut Pasteur in Paris in the fight against bacterial infections of the lungs. The aim of the research is to analyse the role of the Pseudomonas aeruginosa bacterium in the response of lung cells to infections, particularly in cystic fibrosis. This bacterium is highly pathogenic for people who are immunocompromised or weakened and is responsible for a large number of acute and chronic lung infections.
© L. Touqui - Dr Touqui's team
A bacterium with a strong adaptive capacity
The Pseudomonas aeruginosa bacterium has a strong adaptability to a large number of hostile environments. It can also quickly develop a resistance to antibiotics following chronic infections and become very virulent. This leads to a therapeutic impasse and represents a global health threat today.
The Pseudomonas aeruginosa bacterium is classified by the World Health Organization in the critical priority list of multi-resistant bacteria.
Controlling lung infection
The goal of Dr. Touqui and his team at the Institut Pasteur is to find an interesting therapeutic target for the control of pulmonary infection by Pseudomonas aeruginosa, one of the major causes of mortality in patients with cystic fibrosis. The virulence of this bacterium is enhanced by its ability to inject exotoxins directly into the host cell. A better understanding of the role and mode of action of exotoxins would allow a better understanding of how this bacterium settles in a long-term and irreversible manner in the airways of cystic fibrosis patients, but also of immunocompromised patients infected by the bacterium.
ExoY, a key to understanding Pseudomonas aeruginosa
The aim of this research project is to study in particular the exotoxin ExoY, one of the four exotoxins produced by Pseudomonas aeruginosa. Preliminary studies suggest that the exotoxin ExoY stimulates the cellular defense process - phagocytosis - of this bacteria. It may even have an inhibitory effect in inducing the process of self-destruction (apoptosis) of the cells that the bacteria attacks. The study of this exotoxin remains to be developed. Therefore this project aims to analyse the role of ExoY in:
- the regulation of the phagocytosis of Pseudomonas aeruginosa by white blood cells (macrophages)
- the inflammatory response of human respiratory epithelial cells and macrophages
- Pseudomonas aeruginosa-induced self-destruction (apoptosis) of human respiratory cells
How the Air Liquide Foundation is participating
The Air Liquide Foundation is contributing with 150,000 € to the acquisition of the consumables necessary for the research project and the operating costs.
Discover other projects we support
Fighting pulmonary infections
The Air Liquide Foundation is supporting the Institut Pasteur in Paris in its research on bacterial pulmonary infections.
Cystic fibrosis: fighting bacterial superinfection
Identification of molecules controlling the organism's anti-infectious and anti-inflammatory response.
Cystic Fibrosis: research on a new therapeutic target in Germany
Cystic fibrosis is one of the most common congenital metabolic diseases in the European population.
Advances in Research on Treating Cystic Fibrosis
In Belgium, an antibody has been discovered that stabilizes the protein responsible for cystic fibrosis, opening up new possibilities for therapeutic experiments